Our policy in the Medical Programs Department of the National Psoriasis Foundation (NPF) is to ensure balance, independence, objectivity, and scientific rigor in all our educational programs.  Anyone presenting or participating in the planning of any NPF CME programs is expected to disclose to the Medical Programs Department any real or apparent affiliation(s) within the past 12 months that may have a direct bearing on the subject matter of the continuing medical education program.  The intent of this policy is to ensure continuing medical education programs that are free of commercial interests.

The following faculty and planning committee have disclosed the following relationships with commercial interests:


Mark Lebwohl, MD
Dr. Lebwohl is an employee of Mt. Sinai and receives research funds from Abbvie, Amgen, Arcutis, AstraZeneca, Boehringer Ingelheim, Celgene, Clinuvel, Corrona, Inc., Eli Lilly, Foundation for
Research & Education of Dermatology, Incyte, Janssen Research & Development, LLC, Kadmon Corp., LLC, Leo Pharmaceuticals, Medimmune, Novartis, Ortho Dermatologics, Pfizer, Sciderm, UCB, Inc., and ViDac.

Dr. Lebwohl is also a consultant for Allergan, Almirall, Arcuits, Inc., Avotres Therapeutics, BirchBioMed, Inc., Boehringer Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Dermavant Sciences, Inozyme Pharma, LEO Pharma, Meiji Seika Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/Dr. Reddy's Laboratories, Theravance and Verrica.

Planning Committee:

Andi Agnew has disclosed no relevant financial interests with any commercial interests.